Kathryn Bobb

TL;DR: The data show that PBS-1086 is a promising dual inhibitor of the canonical and noncanonical NF-κB pathways, and this preclinical study provides the framework for clinical evaluation of PBS- 1086 in combination with bortezomib for the treatment of multiple myeloma and related bone lesions.

TL;DR: It is indicated that NF-κB activation plays a critical upstream role in the immune activation of HAM/TSP, and the NF-σB pathway is identified as a potential target for immunomodulation in HAM/ TSP.

TL;DR: It is demonstrated that PBS-1086 exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with CIA and reduces the neutrophil infiltration which is a key mediator of RA.

TL;DR: The effect of PBS-1086, a novel small molecule “pan-rel” inhibitor, on viability of patient-derived CLL cells and compared it with BAY 11–7082, an IKKβ inhibitor that affects p65 and p50 was found to be variable among patients, with levels ranging from very high to undetectable.

TL;DR: Results indicate that NFkB activation plays a critical upstream role in the immune activation associated with HAM/TSP, and identify the NFkB pathway as a potential therapeutic target for immune modulation in HAM/ TSP.